DANIELA COUTO

Daniela Couto is a distinguished Partner at BGV (BioGeneration Ventures), a prominent European venture capital firm dedicated to fostering innovation in the life sciences sector. At BGV, Daniela plays a pivotal role in identifying, evaluating, and nurturing early-stage biotech and pharmaceutical companies with the potential to revolutionize healthcare. Her work is instrumental in shaping BGV's investment strategy, particularly in areas poised for significant scientific and commercial breakthroughs.

Daniela's investment focus is primarily centered on groundbreaking early-stage opportunities within the life sciences. This includes novel therapeutic platforms, advanced drug discovery technologies, and companies developing innovative treatments for unmet medical needs. She is particularly interested in ventures that demonstrate robust scientific foundations, strong intellectual property, and clear pathways to clinical development. Her expertise helps BGV portfolio companies navigate the complex landscape of drug development, from preclinical research through to clinical trials.

Prior to joining BGV, Daniela Couto built a robust career foundation rooted in both scientific research and strategic business development. Holding a Ph.D. in Molecular Biology, her early career involved significant contributions to academic research, where she gained invaluable insights into the intricacies of biological systems and disease mechanisms. This scientific rigor was complemented by experience in the pharmaceutical industry, where she was involved in R&D strategy and commercialization efforts for novel compounds. Her unique blend of scientific acumen and business foresight makes her an exceptionally effective investor in the highly specialized biotech sector.

While specific individual investments are often part of BGV's collective portfolio, Daniela Couto is recognized for her instrumental role in identifying and supporting numerous promising ventures that have gone on to achieve significant milestones. She is deeply involved in the strategic development of portfolio companies, providing guidance on scientific direction, team building, and fundraising. Her commitment to fostering innovation ensures that BGV continues to back companies that are at the forefront of medical advancement, ultimately aiming to bring life-changing therapies to patients worldwide. Daniela's leadership at BGV reinforces the firm's reputation as a key player in the global life sciences venture capital landscape.